

Title (en)

NUCLEIC ACID BASED MODULATION OF FEMALE REPRODUCTIVE DISEASES AND CONDITIONS

Title (de)

AUF NUKLEINSÄURE BASIERENDE MODULATION VON KRANKHEITEN UND ERKRANKUNGEN DES WEIBLICHEN REPRODUKTIONSSYSTEMS

Title (fr)

MODULATION A BASE DE L'ACIDE NUCLEIQUE DES MALADIES ET TROUBLES DE L'APPAREIL REPRODUCTEUR CHEZ LA FEMME

Publication

EP 1390385 A4 20041124 (EN)

Application

EP 02752028 A 20020529

Priority

- US 0217674 W 20020529
- US 87016101 A 20010529
- US 33446101 P 20011130
- US 13867402 A 20020503

Abstract (en)

[origin: WO02096927A2] The present invention relates to nucleic acid molecules, including dsRNA, siRNA, antisense, 2,5-A chimeras, aptamers, and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, and allozymes, which modulate the expression of vascular endothelial growth factor receptor (VEGF) and/or vascular endothelial growth factor receptor (VEGFr) genes for the treatment and/or diagnosis of diseases and conditions associated with angiogenesis, such as cancer, tumor angiogenesis, or ocular indications such as diabetic retinopathy, or age related macular degeneration, proliferative diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis, psoriasis, wound healing, and female reproductive disorders and conditions, including but not limited to endometriosis, endometrial carcinoma, gynecologic bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), and menopausal dysfunction.

IPC 1-7

C07H 21/04; C12Q 1/68; C12N 5/00

IPC 8 full level

A61K 9/127 (2006.01); **A61K 31/282** (2006.01); **A61K 31/337** (2006.01); **A61K 31/4745** (2006.01); **A61K 31/519** (2006.01); **A61K 31/7072** (2006.01); **A61K 31/7125** (2006.01); **A61K 38/22** (2006.01); **A61K 45/00** (2006.01); **A61K 47/44** (2006.01); **A61K 48/00** (2006.01); **A61P 3/10** (2006.01); **A61P 5/02** (2006.01); **A61P 9/00** (2006.01); **A61P 9/10** (2006.01); **A61P 15/00** (2006.01); **A61P 15/08** (2006.01); **A61P 15/12** (2006.01); **A61P 15/18** (2006.01); **A61P 17/02** (2006.01); **A61P 17/06** (2006.01); **A61P 19/02** (2006.01); **A61P 21/00** (2006.01); **A61P 27/02** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C12N 5/06** (2006.01); **C12N 15/09** (2006.01); **C12N 15/11** (2006.01); **C12N 15/13** (2010.01); **A61K 38/00** (2006.01)

CPC (source: EP)

A61P 3/10 (2017.12); **A61P 5/02** (2017.12); **A61P 9/00** (2017.12); **A61P 9/10** (2017.12); **A61P 15/00** (2017.12); **A61P 15/08** (2017.12); **A61P 15/12** (2017.12); **A61P 15/18** (2017.12); **A61P 17/02** (2017.12); **A61P 17/06** (2017.12); **A61P 19/02** (2017.12); **A61P 21/00** (2017.12); **A61P 27/02** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 43/00** (2017.12); **C12N 15/1138** (2013.01); **C12N 2310/14** (2013.01); **C12N 2310/315** (2013.01); **C12N 2310/317** (2013.01); **C12N 2310/321** (2013.01); **C12N 2310/322** (2013.01); **C12N 2310/332** (2013.01)

Citation (search report)

- [DY] WO 9715662 A2 19970501 - RIBOZYME PHARM INC [US], et al
- [E] WO 03070910 A2 20030828 - RIBOZYME PHARM INC [US], et al
- [Y] PARRISH S ET AL: "Functional anatomy of a dsRNA trigger: Differential requirement for the two trigger strands in RNA interference", MOLECULAR CELL, vol. 6, no. 5, November 2000 (2000-11-01), pages 1077 - 1087, XP002226298, ISSN: 1097-2765
- [DA] MCLAREN J: "Vascular endothelial growth factor and endometriotic angiogenesis", HUMAN REPRODUCTION UPDATE, vol. 6, no. 1, January 2000 (2000-01-01), pages 45 - 55, XP002298154, ISSN: 1355-4786
- [DA] ELBASHIR SAYDA M ET AL: "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells", NATURE, vol. 411, no. 6836, 24 May 2001 (2001-05-24), pages 494 - 498, XP002206451, ISSN: 0028-0836
- See references of WO 02096927A2

Citation (examination)

ELBASHIR S.M. ET AL: "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate", EMBO JOURNAL, vol. 20, no. 23, 3 December 2001 (2001-12-03), OXFORD UNIVERSITY PRESS, SURREY, GB, pages 6877 - 6888, XP002225998

Cited by

EP4035659A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 02096927 A2 20021205; WO 02096927 A3 20030220; AU 2002344237 B2 20081023; AU 2002344237 B8 20081106;
CA 2448320 A1 20021205; EP 1390385 A2 20040225; EP 1390385 A4 20041124; GB 0404461 D0 20040331; JP 2005500025 A 20050106;
JP 2009000106 A 20090108

DOCDB simple family (application)

US 0217674 W 20020529; AU 2002344237 A 20020529; CA 2448320 A 20020529; EP 02752028 A 20020529; GB 0404461 A 20040227;
JP 2003500106 A 20020529; JP 2008149684 A 20080606